Great News for our European Friends

The European Commission (EC) has approved the marketing authorisation of lutetium (177Lu) oxodotreotide (Lutathera) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.

Read more here: http://ecancer.org/news/12480-european-approval-of-lutetium-oxodotreotide-for-gastroenteropancreatic-neuroendocrine–gep-net–tumours.php

 

We have to be next!!

Join our NET Community

Sign-up for our email newsletter. Simply register with us to receive regular updates.

Register now